查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1869590

照護現場流感診斷市場規模、佔有率和趨勢分析報告：按檢測類型、流感病毒株、技術、最終用途、地區和細分市場預測（2025-2033 年）

Point-of-Care Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type, By Influenza Strain, By Technology, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

照護現場流感診斷市場摘要

2024 年全球照護現場流感診斷市場規模估計為 4.1556 億美元，預計到 2033 年將達到 7.0952 億美元。

預計從 2025 年到 2033 年，該市場將以 6.14% 的複合年成長率成長。季節性和通用流感感染疾病的發生率和嚴重程度增加、快速即時檢測的普及、流感即時檢測技術的進步以及與遠端醫療和居家檢測的結合是推動市場成長的主要因素。

例如，根據國際紅十字會與紅新月會聯合會2023年10月發布的報告，每年約有10億例季節性流感病例，其中300萬至500萬例為重症，導致每年29萬至65萬人死於呼吸道疾病。此外，2024年6月，瑞士羅氏公司（F. Hoffmann-La Roche）的cobas甲型/乙型流感及呼吸道合胞病毒核酸檢測獲得了美國食品食品藥物管理局（FDA）的緊急使用授權（EUA）。此檢測是一種在美國 liat系統上進行的甲型流感多重即時聚合酵素鏈鎖反應（RT-PCR）檢測。此檢測使用小型分析儀，僅需20分鐘即可得出結果，適用於大多數醫療機構，只需採集一份鼻咽拭子或前鼻拭子檢體即可確診或排除甲型和乙型流感病毒感染。

照護現場檢測（POC​​）的快速普及是推動市場成長的關鍵因素。這些快速檢測通常可在數分鐘內得出結果，有助於在門診和急診環境中及時進行診斷和治療決策。快速流感診斷檢測（RIDT）的便利性和易用性降低了對中心檢查室的依賴，縮短了出結果的時間，並改善了患者的治療效果。此外，這些檢測的價格越來越親民，也越來越容易取得，因此可以在包括診所、藥局和急診室在內的各種醫療機構中使用。技術的不斷進步提高了快速檢測的靈敏度和特異性，進一步推動了分散式檢查的發展。因此，醫療機構越來越傾向於將即時檢測納入其常規流感管理流程，從而推動市場成長，尤其是在北美和歐洲，亞太地區的普及率也不斷提高。

推動市場擴張的另一個創新因素是遠端醫療與居家流感檢測的結合。經FDA核准的居家流感檢測套組通常與遠端醫療平台配合使用，支援虛擬諮詢，並將即時結果發送給醫療專業人員，從而實現便捷快速的居家診斷。例如，2024年10月，美國食品藥物管理局（FDA）核准了Healgen Rapid Check流感A&B抗原檢測試劑盒。這款非處方箋檢測套組適用於出現呼吸道症狀的族群，使用鼻拭子檢體，可在約15分鐘內提供新冠病毒和流感檢測結果。此檢測可辨識甲型和乙型流感病毒（引起流感的病毒）的蛋白質。

這種整合有助於公共衛生工作，促進早期發現和隔離，減少流感傳播，同時提高患者接受檢測的便利性和可及性。新冠肺炎疫情推動了居家診斷的發展，並提高了人們對遠距醫療解決方案的認知和接受度。

目錄

第1章照護現場（POC​​）流感診斷市場：調查方法與範圍

第2章照護現場（POC​​）流感診斷市場：執行摘要

  • 市場概述
  • 檢查類型
  • 流感病毒株概況
  • 技術概覽
  • 最終用途簡介
  • 競爭格局概覽

第3章照護現場（POC​​）流感診斷市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素分析
    • 全球季節性和通用流感疫情的盛行率和嚴重程度不斷增加
    • 快速即時檢測（POC​​檢測）的應用日益普及
    • 流感即時檢測技術的進步
    • 整合遠端醫療和居家檢測
  • 市場限制因素分析
    • 先進測試設備高成本
  • 波特五力分析
  • PESTLE分析
  • 管道分析

第4章照護現場（POC​​）流感診斷市場：檢測類型估算與趨勢分析

  • 照護現場流感診斷市場：檢測類型差異分析
  • 照護現場流感診斷市場：按檢測類型分類的展望
  • 快速抗原檢測（RIDT）
  • 分子就地檢驗
  • 基於生物感測器的檢測
  • 其他

第5章照護現場（POC​​）流感診斷市場：流感病毒株估計與趨勢分析

  • 照護現場流感診斷市場：流感病毒株波動分析
  • 照護現場流感診斷市場：按流感株分類的展望
  • 甲型流感
  • 乙型流感
  • 甲型和乙型流感聯合檢測

第6章照護現場流感診斷市場：技術估算與趨勢分析

  • 照護現場流感診斷市場：技術波動分析
  • 照護現場流感診斷市場：技術展望
  • 基於免疫檢測法
  • 分子診斷
  • 基於奈米技術的系統
  • 其他

第7章照護現場（POC​​）流感診斷市場：終端用戶需求預測及趨勢分析

  • 照護現場流感診斷市場：終端用途差異分析
  • 照護現場流感診斷市場：終端用戶展望
  • 醫院
  • 診所
  • 居家照護環境
  • 其他

第8章照護現場（POC​​）流感診斷市場：區域業務分析

  • 區域市場概況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲

第9章 競爭情勢

  • 公司分類
  • 策略規劃
    • 新產品上市
    • 夥伴關係
    • 獲得
    • 合作
    • 資金籌措
  • 主要企業市佔率分析，2024 年
  • 公司熱力圖分析
  • 公司簡介
    • Abbott
    • Becton Dickinson（BD）
    • Danaher/Cepheid
    • Quidel Corporation, Inc
    • Qiagen
    • F. Hoffmann-La Roche Ltd
    • Bio-Rad
    • BioMerieux（Biofire/Idaho Technologies）
    • Diasorin（Focus Diagnostics）
    • Hologic
    • Thermo/Remel
    • Fujirebio.
    • Visby Medical
    • Twist
Product Code: GVR-4-68040-785-8

Point-of-Care Influenza Diagnostics Market Summary

The global point-of-care influenza diagnostics market size was estimated at USD 415.56 million in 2024 and is projected to reach USD 709.52 million by 2033, growing at a CAGR of 6.14% from 2025 to 2033. Increasing global prevalence and severity of seasonal & zoonotic influenza outbreaks, growth in adoption of rapid POC tests, technological advancements in the influenza POC tests, and telehealth & home-based testing integration are key drivers of market growth.

For instance, in October 2023, the International Federation of Red Cross and Red Crescent Societies reported around a billion seasonal flu cases annually, including 3-5 million cases of severe illness, causing 290,000 to 650,000 respiratory deaths annually. Furthermore, in June 2024, F. Hoffmann-La Roche (Switzerland) received approval from the U.S. Food and Drug Administration (FDA) (Emergency Use Authorization (EUA)) for its cobas Influenza A/B & RSV nucleic acid test, an Influenza A multiplex real-time polymerase chain reaction (RT-PCR) assay on the cobas liat system. Producing results in just 20 minutes on a compact analyzer suitable for most healthcare settings, the test uses either a single nasopharyngeal or anterior nasal swab sample to confirm or rule out infection with influenza A and B viruses.

The rapid adoption of point-of-care (POC) tests is a significant factor fostering market growth. These rapid tests provide prompt results, often within minutes, allowing for timely diagnosis and treatment decisions for outpatient and urgent care settings. The convenience and ease of use of rapid influenza diagnostic tests (RIDTs) reduce reliance on centralized laboratories, reduce turnaround time, and improve patient outcomes. Furthermore, these tests are becoming more affordable and accessible, allowing their use in various healthcare settings, such as clinics, pharmacies, and emergency rooms. This shift towards decentralized testing is reinforced by ongoing technological advancements that improve the sensitivity and specificity of rapid tests. Therefore, healthcare providers are more likely to use POC testing as part of routine influenza management, driving market growth, particularly in North America and Europe, with growing adoption in Asia-Pacific markets.

Moreover, one revolutionary factor propelling market expansion is the combination of telehealth and home-based influenza testing. FDA-approved home flu test kits, which are frequently used with telehealth platforms that allow virtual consultations and real-time results transmission to healthcare professionals, have made it possible for people to perform quick diagnostics in the convenience of their own homes. For instance, in October 2024, the Healgen Rapid Check Flu A&B Antigen Test was authorized for sale by the US Food and Drug Administration. The test, available without a prescription and intended for people with respiratory symptoms, uses a nasal swab sample to provide COVID-19 and flu results at home in about 15 minutes. The test can identify proteins from influenza A and B (the viruses that cause the flu).

This integration supports public health initiatives by promoting early detection and isolation, which slows the spread of influenza, and improves patient convenience and testing accessibility. The COVID-19 pandemic made home-based diagnostics easier, raising awareness and acceptance of remote healthcare solutions.

Global Point-of-Care Influenza Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global point-of-care influenza diagnostics market based on test type, influenza strain, technology, end-use, and region:

  • Test Type Outlook (USD Million, 2021 - 2033)
  • Rapid Antigen Tests (RIDT)
  • Molecular Point-of-Care Tests
  • Biosensor-Based Tests
  • Others
  • Influenza Strain Outlook (USD Million, 2021 - 2033)
  • Influenza A
  • Influenza B
  • Influenza A & B Combined Tests
  • Technology Outlook (USD Million, 2021 - 2033)
  • Immunoassay-based
  • Molecular Diagnostics
  • Nanotechnology based Systems
  • Others
  • End-use Outlook (USD Million, 2021 - 2033)
  • Hospitals
  • Clinics
  • Homecare Settings
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Point-of-Care Influenza Diagnostics Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test Type
      • 1.1.1.2. Influenza Strain Segment
      • 1.1.1.3. Technology Segment
      • 1.1.1.4. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Influenza Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Point-of-Care Influenza Diagnostics Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type
  • 2.3. Influenza Strain Snapshot
  • 2.4. Technology Snapshot
  • 2.5. End Use Snapshot
  • 2.6. Competitive Landscape Snapshot

Chapter 3. Point-of-Care Influenza Diagnostics Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing global prevalence and severity of seasonal and zoonotic influenza outbreaks
    • 3.4.2. Growth in adoption of rapid POC tests
    • 3.4.3. Technological advancements in the influenza POC tests
    • 3.4.4. Telehealth & home-based testing integration
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of advanced testing equipment
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis
  • 3.8. Pipeline Analysis

Chapter 4. Point-of-Care Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. Point-of-Care Influenza Diagnostics Market: Test Type Movement Analysis
  • 4.2. Point-of-Care Influenza Diagnostics Market by Test Outlook (USD Million)
  • 4.3. Rapid Antigen Tests (RIDT)
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Molecular Point-of-Care Tests
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Biosensor-Based Tests
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Point-of-Care Influenza Diagnostics Market: Influenza Strain Estimates & Trend Analysis

  • 5.1. Point-of-Care Influenza Diagnostics Market: Influenza Strain Movement Analysis
  • 5.2. Point-of-Care Influenza Diagnostics Market by Influenza Strain Outlook (USD Million)
  • 5.3. Influenza A
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Influenza B
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Influenza A & B Combined Tests
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Point-of-Care Influenza Diagnostics Market: Technology Estimates & Trend Analysis

  • 6.1. Point-of-Care Influenza Diagnostics Market: Technology Movement Analysis
  • 6.2. Point-of-Care Influenza Diagnostics Market by Technology Outlook (USD Million)
  • 6.3. Immunoassay-based
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Molecular Diagnostics
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Nanotechnology based Systems
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Point-of-Care Influenza Diagnostics Market: End Use Estimates & Trend Analysis

  • 7.1. Point-of-Care Influenza Diagnostics Market: End Use Movement Analysis
  • 7.2. Point-of-Care Influenza Diagnostics Market by End Use Outlook (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Homecare Settings
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Others
    • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Point-of-Care Influenza Diagnostics Market: Regional Business Analysis

  • 8.1. Regional Market Snapshot
  • 8.2. North America
    • 8.2.1. North America Point-of-Care Influenza Diagnostics Market Estimates and Forecast, 2021 - 2033 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. U.S. Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.2.2. Key Country Dynamics
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. Reimbursement Scenario
      • 8.2.2.5. Competitive Scenario
    • 8.2.3. Canada
      • 8.2.3.1. Canada Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.3.2. Key Country Dynamics
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Reimbursement Scenario
      • 8.2.3.5. Competitive Scenario
    • 8.2.4. Mexico
      • 8.2.4.1. Mexico Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.2.4.2. Key Country Dynamics
      • 8.2.4.3. Regulatory Framework
      • 8.2.4.4. Reimbursement Scenario
      • 8.2.4.5. Competitive Scenario
  • 8.3. Europe
    • 8.3.1. Europe Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. UK Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.2.2. Key Country Dynamics
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. Reimbursement Scenario
      • 8.3.2.5. Competitive Scenario
    • 8.3.3. Germany
      • 8.3.3.1. Germany Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.3.2. Key Country Dynamics
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Reimbursement Scenario
      • 8.3.3.5. Competitive Scenario
    • 8.3.4. Spain
      • 8.3.4.1. Spain Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.4.2. Key Country Dynamics
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. Reimbursement Scenario
      • 8.3.4.5. Competitive Scenario
    • 8.3.5. France
      • 8.3.5.1. France Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.5.2. Key Country Dynamics
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Reimbursement Scenario
      • 8.3.5.5. Competitive Scenario
    • 8.3.6. Italy
      • 8.3.6.1. Italy Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.6.2. Key Country Dynamics
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Reimbursement Scenario
      • 8.3.6.5. Competitive Scenario
    • 8.3.7. Denmark
      • 8.3.7.1. Denmark Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.7.2. Key Country Dynamics
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Reimbursement Scenario
      • 8.3.7.5. Competitive Scenario
    • 8.3.8. Sweden
      • 8.3.8.1. Sweden Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.8.2. Key Country Dynamics
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Reimbursement Scenario
      • 8.3.8.5. Competitive Scenario
    • 8.3.9. Norway
      • 8.3.9.1. Norway Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.3.9.2. Key Country Dynamics
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Reimbursement Scenario
      • 8.3.9.5. Competitive Scenario
  • 8.4. Asia Pacific
    • 8.4.1. Asia-Pacific Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Japan Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.2.2. Key Country Dynamics
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Scenario
      • 8.4.2.5. Competitive Scenario
    • 8.4.3. China
      • 8.4.3.1. China Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.3.2. Key Country Dynamics
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Scenario
      • 8.4.3.5. Competitive Scenario
    • 8.4.4. India
      • 8.4.4.1. India Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.4.2. Key Country Dynamics
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Scenario
      • 8.4.4.5. Competitive Scenario
    • 8.4.5. South Korea
      • 8.4.5.1. South Korea Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.5.2. Key Country Dynamics
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Reimbursement Scenario
      • 8.4.5.5. Competitive Scenario
    • 8.4.6. Thailand
      • 8.4.6.1. Thailand Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.6.2. Key Country Dynamics
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Reimbursement Scenario
      • 8.4.6.5. Competitive Scenario
    • 8.4.7. Australia
      • 8.4.7.1. Australia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.4.7.2. Key Country Dynamics
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. Reimbursement Scenario
      • 8.4.7.5. Competitive Scenario
  • 8.5. Latin America
    • 8.5.1. Latin America Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Brazil Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.2.2. Key Country Dynamics
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Scenario
      • 8.5.2.5. Competitive Scenario
    • 8.5.3. Argentina
      • 8.5.3.1. Argentina Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.5.3.2. Key Country Dynamics
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Scenario
      • 8.5.3.5. Competitive Scenario
  • 8.6. MEA
    • 8.6.1. MEA Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. South Africa Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.2.2. Key Country Dynamics
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Scenario
      • 8.6.2.5. Competitive Scenario
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Saudi Arabia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.3.2. Key Country Dynamics
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Scenario
      • 8.6.3.5. Competitive Scenario
    • 8.6.4. UAE
      • 8.6.4.1. UAE Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.4.2. Key Country Dynamics
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Scenario
      • 8.6.4.5. Competitive Scenario
    • 8.6.5. Kuwait
      • 8.6.5.1. Kuwait Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
      • 8.6.5.2. Key Country Dynamics
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Scenario
      • 8.6.5.5. Competitive Scenario

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. New Product Launch
    • 9.2.2. Partnerships
    • 9.2.3. Acquisition
    • 9.2.4. Collaboration
    • 9.2.5. Funding
  • 9.3. Key Company Market Share Analysis, 2024
  • 9.4. Company Heat Map Analysis
  • 9.5. Company Profiles
    • 9.5.1. Abbott
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Becton Dickinson (BD)
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Danaher/Cepheid
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Quidel Corporation, Inc
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Qiagen
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. Hoffmann-La Roche Ltd
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Bio-Rad
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. BioMerieux (Biofire/Idaho Technologies)
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Diasorin (Focus Diagnostics)
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Hologic
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. Thermo/Remel
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Fujirebio.
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Visby Medical
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives
    • 9.5.14. Twist
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Financial Performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Point-of-Care Influenza Diagnostics Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 5 Global Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 6 Global Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 Global Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 8 North America Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033 (USD Million)
  • Table 9 North America Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 10 North America Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 11 North America Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 12 North America Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 13 U.S. Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 14 U.S. Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 15 U.S. Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 16 U.S. Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Canada Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033, (USD Million)
  • Table 18 Canada Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033, (USD Million)
  • Table 19 Canada Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033, (USD Million)
  • Table 20 Canada Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 21 Mexico Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 23 Mexico Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 Mexico Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 25 Europe Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 26 Europe Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 27 Europe Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 28 Europe Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 29 Europe Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 UK Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 31 UK Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 32 UK Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 UK Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 34 Germany Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 35 Germany Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 36 Germany Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 37 Germany Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 38 France Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 39 France Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 40 France Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 41 France Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Italy Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 43 Italy Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 44 Italy Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 45 Italy Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 46 Spain Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 47 Spain Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 48 Spain Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 49 Spain Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 50 Sweden Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 51 Sweden Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 52 Sweden Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 53 Sweden Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 54 Norway Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 55 Norway Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 56 Norway Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 57 Norway Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 Denmark Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 59 Denmark Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 60 Denmark Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 61 Denmark Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 63 Asia Pacific Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 65 Asia-Pacific Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 Japan Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 68 Japan Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 69 Japan Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 70 Japan Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 71 China Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 72 China Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 73 China Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 74 China Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 75 India Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 76 India Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 77 India Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 78 India Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 79 Australia Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 80 Australia Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 81 Australia Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 82 Australia Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 83 Thailand Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 84 Thailand Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 85 Thailand Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 86 Thailand Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 South Korea Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 88 South Korea Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 89 South Korea Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 90 South Korea Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 91 Latin America Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 92 Latin America Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 94 Latin America Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 95 Latin America Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 96 Brazil Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 98 Brazil Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 99 Brazil Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 100 Argentina Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 102 Argentina Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 103 Argentina Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 104 MEA Point-of-Care Influenza Diagnostics Market, By Country, 2021 - 2033, (USD Million)
  • Table 105 MEA Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 106 MEA Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 107 MEA Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 108 MEA Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 109 South Africa Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 111 South Africa Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 112 South Africa Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 117 UAE Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 118 UAE Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 119 UAE Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 120 UAE Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Point-of-Care Influenza Diagnostics Market, By Test Type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Point-of-Care Influenza Diagnostics Market, By Influenza Strain, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Point-of-Care Influenza Diagnostics Market, By Technology, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Point-of-Care Influenza Diagnostics Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global Point-of-Care Influenza Diagnostics Market - Key market driver analysis
  • Fig. 7 Global Point-of-Care Influenza Diagnostics Market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global Point-of-Care Influenza Diagnostics Market - Porter's analysis
  • Fig. 10 Global Point-of-Care Influenza Diagnostics Market - PESTEL analysis
  • Fig. 11 Global Point-of-Care Influenza Diagnostics Market: Test Type outlook key takeaways
  • Fig. 12 Global Point-of-Care Influenza Diagnostics Market: Test Type movement analysis
  • Fig. 13 Rapid Antigen Tests (RIDT) Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Molecular Point-of-Care Tests Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Biosensor-Based Tests Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Global Point-of-Care Influenza Diagnostics Market Technology outlook key takeaways
  • Fig. 18 Global Point-of-Care Influenza Diagnostics Market: Technology movement analysis
  • Fig. 19 Influenza A Point-of-Care Influenza Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 20 Influenza B Point-of-Care Influenza Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 21 Influenza A & B Combined Tests Point-of-Care Influenza Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Global Point-of-Care Influenza Diagnostics Market: Technology outlook key takeaways
  • Fig. 23 Global Point-of-Care Influenza Diagnostics Market: Technology movement analysis
  • Fig. 24 Immunoassay-based Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Molecular Diagnostics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 26 Nanotechnology based Systems Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 27 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Global Point-of-Care Influenza Diagnostics Market: End Use outlook key takeaways
  • Fig. 29 Global Point-of-Care Influenza Diagnostics Market: End Use movement analysis
  • Fig. 30 Hospitals Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 31 Clinics Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 32 Homecare Settings Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 33 Others Market Estimates, 2021 - 2033 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Global Point-of-Care Influenza Diagnostics Market: Regional movement analysis
  • Fig. 36 North America Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 37 U.S. Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 39 Mexico Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 40 Europe Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 41 UK Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 43 France Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 44 Spain Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 46 Denmark Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 47 Sweden Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 49 Asia Pacific Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 50 Japan Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 51 China Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 52 India Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 53 South Korea Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 54 Australia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 55 Thailand Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 56 Latin America Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 57 Brazil Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 58 Argentina Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 59 MEA Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 60 South Africa Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 61 Saudi Arabia Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 62 UAE Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 63 Kuwait Point-of-Care Influenza Diagnostics Market, 2021 - 2033 (USD Million)
  • Fig. 64 Strategy framework